A T-cell test developed by Adaptive Biotechnologies could become the first commercially available test of its kind, and it may be more effective at detecting past COVID-19 infections than antibody ...
Researchers at the First Affiliated Hospital of the University of Science and Technology of China claim that an in vivo CD8 T-cell-targeted lipid nanoparticle carrying CD19 CAR mRNA (HN2301) generated ...
HC Wainwright initiated coverage on Virax Biolabs with a Buy rating and a $3 price target, citing strong market potential. ViraxImmune platform aims to diagnose T-cell exhaustion in post-viral ...
SEATTLE, June 15, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into ...
News-Medical.Net on MSN
Epigenetic editing enables safer and more effective T cell therapies
Arc Institute, Gladstone Institutes, and University of California, San Francisco, scientists have developed an epigenetic ...
Finding out if you have celiac disease is not easy. Diagnosing the autoimmune disease in the United States requires two tests. First, a blood test to identify elevated levels of certain antibodies, ...
Novoviah Pharmaceuticals announces that their novel clinical platform technology for detecting and monitoring disease by measuring immune reactivity has been successfully tested in Celiac Disease, ...
15hon MSN
Decoding the T cell burst: Signature genes predict T cell expansion in cancer immunotherapy
The ability of immune cells—particularly CD8+ T cells—to launch a rapid burst of proliferation inside tumors is key to the ...
Immune cells can target cancer in the clinic. The ability to test a gene-editing technology in mice on a large scale should improve such immunotherapies. Michael Hudecek is in the Department of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results